About Biogen

Biogen is a leading global biotechnology company that pioneers science and drives innovations for complex and devastating diseases. Biogen is advancing a pipeline of potential therapies across neurology, neuropsychiatry, specialized immunology and rare disease and remains acutely focused on its purpose of serving humanity through science while advancing a healthier, more sustainable and equitable world.

Founded in 1978, Biogen has pioneered multiple breakthrough innovations including a broad portfolio of medicines to treat multiple sclerosis, the first approved treatment for spinal muscular atrophy, and two co-developed treatments to address a defining pathology of Alzheimer’s disease. In Canada, Biogen has been delivering life-changing medicines and services to Canadians affected by neurological conditions and rare disease for more than 25 years. Our team’s pioneering spirit and firm commitment to patients with complex diseases fuels our drive to innovate and help Canadians access ground-breaking treatments that can transform health, well-being and quality of life.

Where science meets humanity

Science that transforms patient lives. Science that seeks to solve societal problems. Science that acts with purpose. Science that is inspired by the diversity and passion of our people. Discover where science meets humanity at Biogen.

Science & Innovation

R&D Expertise
Our deep scientific expertise and our courage to take risks make us leaders in the research and development of medicines.

Medicines
Our medicines aim to improve the well-being of people around the world.

Manufacturing
Our technology and engineering capabilities help bring our high-quality medicines to market.

Responsibility

Advancing a healthier, more sustainable and equitable world.

Caring Deeply. Working Fearlessly. Changing Lives. ™

Our culture unites the people of Biogen within a spirit of ethics, inclusivity, agility and unwavering patient focus.

Join Our Team

Join our mission to bring transformative medicines to those who need them most.